Publications by authors named "Obach Merce"

Claim this Profile
R
Reporting reimbursement price decisions for onco-hematology drugs in Spain.
David Elvira, Ferran Torres, Roser Vives, Gemma Puig, Mercè Obach

Front Public Health· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Carolina Iglesias-López, Antònia Agustí, Antoni Vallano, Mercè Obach

Value Health· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue.
Alba Gonzalez-Franquesa, Pau Gama-Perez, Marta Kulis, Karolina Szczepanowska, Norma Dahdah, Merce Obach

Redox Biol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory and clinical development to support the approval of advanced therapies medicinal products in Japan.
Iglesias-Lopez Carolina, Agustí Antònia, Obach Mercè, Vallano Antonio

Expert Opin Biol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain).
Montse Gasol, Noelia Paco, Laura Guarga, Josep Àngel Bosch, Caridad Pontes

J Clin Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current landscape of clinical development and approval of advanced therapies.
Carolina Iglesias-Lopez, Antonia Agustí, Antoni Vallano, Merce Obach

Mol Ther Methods Clin Dev· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union.
Carolina Iglesias-Lopez, Antònia Agustí, Antonio Vallano, Merce Obach

Front Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies.
David Elvira, Mercè Obach, Caridad Pontes

BMC Health Serv Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Carolina Iglesias-Lopez, Mercè Obach, Antonio Vallano, Antonia Agustí

Cytotherapy· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha1-antitrypsin ameliorates islet amyloid-induced glucose intolerance and β-cell dysfunction.
Júlia Rodríguez-Comas, Juan Moreno-Vedia, Mercè Obach, Carlos Castaño, Sara de Pablo

Mol Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines.
Jane Moseley, Spiros Vamvakas, Michael Berntgen, Alison Cave, Xavier Kurz

Br J Clin Pharmacol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States.
Carolina Iglesias-Lopez, Antonia Agustí, Mercè Obach, Antonio Vallano

Front Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Caridad Pontes, Corinne Zara, Josep Torrent-Farnell, Merce Obach, Cristina Nadal

Appl Health Econ Health Policy· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States.
Carolina Iglesias-López, Antonia Agustí, Mercè Obach, Antonio Vallano

Front Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut).
Laura Guarga, Xavier Badia, Mercè Obach, Manel Fontanet, Alba Prat

Orphanet J Rare Dis· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of autoimmune diabetes and islet allograft rejection by beta cell expression of XIAP: Insight into possible mechanisms of local immunomodulation.
Mercè Obach, Azadeh Hosseini-Tabatabaei, Joel Montane, Katarina Wind, Galina Soukhatcheva

Mol Cell Endocrinol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations.
Giovanni Tafuri, Inês Lucas, Steve Estevão, Jane Moseley, Anne d'Andon

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-induced β-cell dysfunction and islet inflammation are ameliorated by 4-phenylbutyrate (PBA) treatment.
Joel Montane, Sara de Pablo, Carlos Castaño, Júlia Rodríguez-Comas, Lisa Cadavez

FASEB J· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological treatment of Alzheimer's disease in the population of Catalonia, Spain.
Mercè Obach, Pilar Lopez, Arantxa Catalan

Med Clin (Barc)· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.
Giovanni Tafuri, Margherita Pagnini, Jane Moseley, Marco Massari, Frank Petavy

Br J Clin Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCL22 Prevents Rejection of Mouse Islet Allografts and Induces Donor-Specific Tolerance.
Joel Montane, Merce Obach, Sigrid Alvarez, Loraine Bischoff, Derek L Dai

Cell Transplant· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein disulfide isomerase ameliorates β-cell dysfunction in pancreatic islets overexpressing human islet amyloid polypeptide.
Joel Montane, Sara de Pablo, Mercè Obach, Lisa Cadavez, Carlos Castaño

Mol Cell Endocrinol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-like Growth Factor 2 Overexpression Induces β-Cell Dysfunction and Increases Beta-cell Susceptibility to Damage.
Alba Casellas, Cristina Mallol, Ariana Salavert, Veronica Jimenez, Miquel Garcia

J Biol Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonviral-mediated hepatic expression of IGF-I increases Treg levels and suppresses autoimmune diabetes in mice.
Xavier M Anguela, Sabrina Tafuro, Carles Roca, David Callejas, Judith Agudo

Diabetes· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular endothelial growth factor-mediated islet hypervascularization and inflammation contribute to progressive reduction of β-cell mass.
Judith Agudo, Eduard Ayuso, Veronica Jimenez, Alba Casellas, Cristina Mallol

Diabetes· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis